NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives $8.50 Average Price Target from Analysts

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $8.50.

Several research analysts have recently weighed in on NRSN shares. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock opened at $0.68 on Monday. The business’s 50 day moving average price is $0.77 and its 200 day moving average price is $0.82. The company has a market cap of $22.27 million, a price-to-earnings ratio of -1.27 and a beta of 1.58. NeuroSense Therapeutics has a one year low of $0.63 and a one year high of $2.10.

Insider Buying and Selling

In other news, CEO Alon Ben-Noon purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the transaction, the chief executive officer owned 4,534,233 shares in the company, valued at $3,627,386.40. This represents a 5.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the acquisition, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at $1,203,240. The trade was a 19.94% increase in their position. The disclosure for this purchase is available in the SEC filing. 27.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On NeuroSense Therapeutics

Large investors have recently modified their holdings of the business. Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth about $26,000. Jane Street Group LLC purchased a new position in NeuroSense Therapeutics during the second quarter worth about $54,000. Yorkville Advisors Global LP purchased a new position in NeuroSense Therapeutics during the fourth quarter worth about $77,000. Finally, Squarepoint Ops LLC increased its position in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares during the last quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.